TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.
Leukemia
; 22(9): 1790-2, 2008 Sep.
Article
in En
| MEDLINE
| ID: mdl-18354492
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyrrolidines
/
Sulfonamides
/
Erythroid Cells
/
Myeloproliferative Disorders
Limits:
Humans
Language:
En
Journal:
Leukemia
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
Year:
2008
Document type:
Article